ClinicalTrials.gg
CompletedNCT05397041Updated Jul 6, 2023

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

A Phase 1 interventional study of BMB-101 and Placebo in Healthy, sponsored by Bright Minds Biosciences Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Bright Minds Biosciences Pty Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is designed as a single centre, double blind, placebo controlled, randomized, SAD/FE/MAD, safety, tolerance and PK study of BMB-101 in healthy adult subjects. The study will be conducted as a 3-part study.

Read the detailed description

This study is designed as a 3-part study:

Part 1 is designed as single ascending dose (SAD) escalation study investigating 4 dose levels. Each cohort will consist of participants to be randomly assigned to receive a blinded oral dose of BMB-101 or placebo.

Part 2 is designed as a randomized, orally administered, single-dose, two-treatment (fed vs fasted), two-period, two-sequence crossover to assess the effects of a standard high-fat breakfast on PK of BMB-101.

Part 3 is designed as a multiple ascending dose (MAD) escalation study investigating up to 4 dose levels. Subjects will be randomized to receive double-blind treatment of BMB-101 or matching placebo twice daily for 7 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Bright Minds Biosciences Pty Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Subject must be aged between 18 and 55 years (both inclusive).
  2. Healthy subjects with no screening results.
  3. (BMI) 18.0 to 32.0 kg/m².
  4. Males and non pregnant females willing to use consistent with local regulations from screening through 3 months after the last dose of study medication.
  5. Agree to frequent blood and urine sampling during the course of the study.
  6. Agree to be confined in the study unit and follow study procedures.

Key Exclusion Criteria:

  1. Subjects with unstable or severe illness as indicated on medical history, physical examination, or clinical laboratory, vital signs, and (ECGs) evaluations, or in the opinion of the Investigator.
  2. Subjects with reported history within past 6 months of, or current treatment for, any GI disease that may impact the absorption of an oral drug for example gastroesophageal reflux disorder, peptic ulcer disease, inflammatory bowel disease.
  3. Subjects with a history of seizures other than febrile seizures as a child.
  4. Subjects with history of or current glucose intolerance; or with history of gestational diabetes.
  5. Subjects with lifetime history of suicidal behavior or with lifetime history of suicidal ideation as indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS)
  6. Subjects with any use of or intent to use any medications, including prescription, over-the-counter (OTC), herbal preparations, or vitamin/mineral supplementation, other than study medications, from 7 days prior to first dose through follow-up visit.
  7. Female subjects with a positive pregnancy test at Screening or Day -1 or who are breastfeeding.
  8. Subjects who have used more than 5 cigarettes, cigars, or nicotine-containing products per month within 6 months prior to first study dose, or plan to use them through completion of the follow-up visit.
  9. Subjects with a positive drug screen for illegal drugs including cannabis at Screening or Day -1.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    BMB-101

    Participants receiving BMB-101 orally

    Drug: BMB-101

  • Placebo comparator
    Placebo

    Participants receiving Matched Placebo orally

    Drug: Placebo

Interventions

  • Participants will receive one of several different oral doses of BMB-101 once or twice daily

  • DrugPlacebo

    Matched Placebo

06

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent Adverse Events

    Incidence and severity of adverse events, including serious adverse events and adverse events, clinically significant changes in laboratory testing, vital signs, Holter monitoring, physical examination, and ECGs

    Time frame: Baseline up to Follow Up/End of Treatment visit, an average of 8 months.

  2. Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Response

    Type of Suicidal Ideation, Intensity (1 - 5, with 5 being most severe), Suicidal Behavior

    Time frame: Administered at each of the following visits in Part 3: Screening, Clinic Discharge, and Follow-up/Early Withdrawal.

Secondary outcomes

  1. Pharmacokinetic Assessment

    Concentration of BMB-101 in Plasma and Urine samples: * SAD - 13 blood collection timepoints \& 8 urine PK collection periods over 4 days (Day 1 through End of Dosing period) * FE - 10 blood collection timepoints over 4 days (Day 1 through End of Dosing period) - 20 blood collection timepoints in total as 2 periods in FE * MAD - 23 blood collection timepoints \& 8 urine PK collection periods over 7 days (Day 1 through End of Dosing period)

    Time frame: Day 1 through End of Dosing Period.

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in May 2023, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 31, 2022
StartActual
Jun 6, 2022
Primary completionActual
May 4, 2023
CompletionActual
May 4, 2023
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05397041
Lead sponsor
Bright Minds Biosciences Pty Ltd
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Jun 6, 2022
Primary completion
May 4, 2023
Completion
May 4, 2023
Last update
Jul 6, 2023

Study contacts

Michele De Sciscio
principal investigator · CMAX Clinical Research

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMB-101

Start the discussion